United States v. Rosenthal

445 F.3d 1239, 2006 WL 1084337
CourtCourt of Appeals for the Ninth Circuit
DecidedApril 25, 2006
Docket03-10307, 03-10370
StatusPublished
Cited by7 cases

This text of 445 F.3d 1239 (United States v. Rosenthal) is published on Counsel Stack Legal Research, covering Court of Appeals for the Ninth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Rosenthal, 445 F.3d 1239, 2006 WL 1084337 (9th Cir. 2006).

Opinion

BETTY B. FLETCHER, Circuit Judge.

Edward Rosenthal appeals a three-count conviction for violations of the Controlled Substances Act (“CSA”), 21 U.S.C. §§ 801 et seq., asserting an as-applied Commerce Clause challenge, a claim of immunity pursuant to 21 U.S.C. § 885(d), erroneous evidentiary rulings and instructions by the district court, prosecutorial misconduct, juror misconduct, and the improper denial of a hearing under Franks v. Delaware, 438 U.S. 154, 98 S.Ct. 2674, 57 L.Ed.2d 667 (1978). The government cross-appeals, claiming that the district court erroneously found Rosenthal eligible for the “safety valve” and erroneously departed downward to impose a single day of confinement.

We have jurisdiction pursuant to 28 U.S.C. § 1291 and 18 U.S.C. § 3742(b), and we reverse the conviction solely on the issue of jury misconduct. We affirm the district court on all other grounds and dismiss the government’s claims regarding sentencing as moot.

I

In November 1996, Californians passed, by voter initiative, Proposition 215, the Compassionate Use Act, which allows patients to obtain marijuana for “personal medical purposes ... upon the written or oral recommendation or approval of a physician.” Cal. Health & Safety Code § 11362.5(d). One of the purposes of the Compassionate Use Act is

[t]o ensure that seriously ill Californians have the right to obtain and use marijuana for medical purposes where that medical use is deemed appropriate and has been recommended by a physician who has determined that the person’s health would benefit from the use of marijuana in the treatment of cancer, anorexia, AIDS, chronic pain, spasticity, glaucoma, arthritis, migraine, or any other illness for which marijuana provides relief.

Id. The statute shields patients and their primary caregivers from prosecution under *1241 state-law provisions outlawing the possession and cultivation of marijuana. See id. § 11362.5(d).

A

After passage of the Compassionate Use Act, a number of “medical cannabis dispensaries” were formed to make marijuana accessible to seriously ill patients. In support of those efforts, the Oakland City Council, on July 28, 1998, adopted Ordinance No. 12076 (“the Oakland Ordinance”), which intends to “ensure access to safe and affordable medical cannabis pursuant to the Compassionate Use Act of 1996.” Oakland, Cal., Ordinance 12076 § 1(C) (July 28, 1998) (codified as amended at Oakland, Cal., Mun. Code ch. 8.46). The Oakland Ordinance purports to “provide immunity to medical cannabis provider associations pursuant to Section 885(d) of Title 21 of the United States Code.” Id. § 1(D). Under the Ordinance, the City Manager designates “one or more entities as a medical cannabis provider association.” 1 That entity would then designate individuals to help distribute medical cannabis to seriously ill persons.

The City of Oakland designated the Oakland Cannabis Buyers’ Cooperative (“OCBC”) an official medical-cannabis-provider association. Jeffrey Jones, OCBC’s executive director, designated Rosenthal to be an agent of the OCBC and to cultivate marijuana plants for distribution to authorized medical-cannabis users. That designation, memorialized in a letter from Jones to Rosenthal on September 4, 1998, specifically states that “you are deemed a duly authorized ‘officer of the City of Oakland’ and as such are immune from civil and criminal liability under Section 885(d) of the federal Controlled Substances Act.”

B

After California’s approval of the Compassionate Use Act, questions surfaced as to whether cannabis dispensaries actually were immune from prosecution under state and federal drug laws. In 1997, a California Court of Appeal held that cannabis-cultivating clubs are not “primary caregivers” within the meaning of the Compassionate Use Act and are therefore not shielded from prosecution under the state’s controlled-substanees laws. See People ex rel. Lungren v. Peron, 59 Cal. App.4th 1383, 70 Cal.Rptr.2d 20, 31-32 (1997). 2 On May 19, 1998, the same district court from which the instant appeal is taken entered a preliminary injunction order barring the OCBC (and five other cannabis dispensaries) from manufacturing, distributing, or possessing marijuana with the intent to manufacture or distribute, in violation of federal law. See United States v. Cannabis Cultivators Club, 5 F.Supp.2d 1086, 1106(N.D.Cal.1998).

The OCBC, after designation as an official cannabis dispensary, sought dismissal of the complaint, but the district court denied that request, rejecting the OCBC’s claim that the Oakland Ordinance immunized it from federal liability under 21 U.S.C. § 885(d). The district court further denied OCBC’s requests to modify the injunction to permit an exception in cases of medical necessity. 3

*1242 Rosenthal continued cultivating marijuana for distribution to both the OCBC and San Francisco’s Harm Reduction Center from October 2001 until February 12, 2002, the day of his arrest.

C

Rosenthal filed a series of pre-trial motions and, eventually, a motion to dismiss the indictment. He claimed his prosecution exceeded the federal government’s powers under the Commerce Clause, violating the Tenth Amendment to the U.S. Constitution; that the government engaged in selective prosecution; that he was immune from prosecution under the federal immunity provision; and that the indictment was tainted due to entrapment-by-estoppel. The district court denied all of Rosenthal’s motions. It also granted the government’s motions in limine, which precluded Rosenthal from putting on a “medical marijuana” defense, introducing evidence or argument aimed at jury nullification, or introducing evidence or argument related to an entrapment-by-estoppel defense.

D

On January 31, 2003, at the conclusion of the trial, the jury found Rosenthal guilty of one count of manufacturing marijuana, in violation of 21 U.S.C. § 841(a)(1); one count of conspiracy to manufacture marijuana, in violation of 21 U.S.C. § 846; and one count of maintaining a place for the manufacture of marijuana, in violation of 21 U.S.C. § 856(a)(1).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

State v. Ehrensing
296 P.3d 1279 (Court of Appeals of Oregon, 2013)
United States v. Berger
Ninth Circuit, 2007
United States v. Ramos
481 F. Supp. 2d 717 (W.D. Texas, 2006)
United States v. Benally
203 F. App'x 816 (Ninth Circuit, 2006)
United States v. Rosenthal
Ninth Circuit, 2006

Cite This Page — Counsel Stack

Bluebook (online)
445 F.3d 1239, 2006 WL 1084337, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-rosenthal-ca9-2006.